Off-label use of treprostinil in adult patients in clinical cases.

IF 1 4区医学 Q3 MEDICINE, GENERAL & INTERNAL

World Journal of Clinical Cases Pub Date : 2025-08-16 DOI:10.12998/wjcc.v13.i23.107279

Christina Mouratidou, Efstathios T Pavlidis, Georgios Katsanos, Serafeim-Chrysovalantis Kotoulas, Georgios Tsoulfas, Eleni Mouloudi, Ioannis A Taitzoglou, Ioannis N Galanis, Theodoros E Pavlidis

{"title":"Off-label use of treprostinil in adult patients in clinical cases.","authors":"Christina Mouratidou, Efstathios T Pavlidis, Georgios Katsanos, Serafeim-Chrysovalantis Kotoulas, Georgios Tsoulfas, Eleni Mouloudi, Ioannis A Taitzoglou, Ioannis N Galanis, Theodoros E Pavlidis","doi":"10.12998/wjcc.v13.i23.107279","DOIUrl":null,"url":null,"abstract":"<p><p>Treprostinil is a relatively new tricyclic prostacyclin analog with a stable structure, extended half-life and improved potency. Currently, treprostinil is indicated by the Food and Drug Administration in the United States for the treatment of pulmonary arterial hypertension (group 1 in the pulmonary hypertension classification of the World Health Organization). It has a potent vasodilating effect along with the inhibition of platelet aggregation and the attenuation of the inflammatory response in pulmonary and systemic circulation. It is available in the following formulations: Subcutaneous, intravenous, inhaled and oral. Although unknown to many clinicians, several encouraging reports of off-label treprostinil use in the adult population suggest its potential effectiveness in other clinical conditions. Currently under investigation are digital ischemia secondary to systemic sclerosis, chronic limb ischemia, hepatic ischemia-reperfusion injury and group 3 and 4 pulmonary hypertension. Based on review and analysis of the available literature, this article provides a thorough update on the off-label use of treprostinil in adult patients.</p>","PeriodicalId":23912,"journal":{"name":"World Journal of Clinical Cases","volume":"13 23","pages":"107279"},"PeriodicalIF":1.0000,"publicationDate":"2025-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12188765/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Clinical Cases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.12998/wjcc.v13.i23.107279","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Treprostinil is a relatively new tricyclic prostacyclin analog with a stable structure, extended half-life and improved potency. Currently, treprostinil is indicated by the Food and Drug Administration in the United States for the treatment of pulmonary arterial hypertension (group 1 in the pulmonary hypertension classification of the World Health Organization). It has a potent vasodilating effect along with the inhibition of platelet aggregation and the attenuation of the inflammatory response in pulmonary and systemic circulation. It is available in the following formulations: Subcutaneous, intravenous, inhaled and oral. Although unknown to many clinicians, several encouraging reports of off-label treprostinil use in the adult population suggest its potential effectiveness in other clinical conditions. Currently under investigation are digital ischemia secondary to systemic sclerosis, chronic limb ischemia, hepatic ischemia-reperfusion injury and group 3 and 4 pulmonary hypertension. Based on review and analysis of the available literature, this article provides a thorough update on the off-label use of treprostinil in adult patients.

查看原文本刊更多论文

成人患者超说明书使用曲前列汀的临床案例。

treprostiil是一种结构稳定、半衰期延长、效价提高的新型三环前列环素类似物。目前，美国食品和药物管理局（Food and Drug Administration）指出，曲前列替尼可用于治疗肺动脉高压（世界卫生组织肺动脉高压分类中的第1组）。它具有强大的血管扩张作用，同时抑制血小板聚集和减弱肺循环和体循环中的炎症反应。它有以下剂型：皮下注射、静脉注射、吸入和口服。尽管许多临床医生不知道，一些令人鼓舞的报告表明，在成人人群中使用说明书外的曲前列地尼表明它在其他临床条件下可能有效。目前正在研究的是继发于系统性硬化症的手指缺血、慢性肢体缺血、肝缺血再灌注损伤和第3组和第4组肺动脉高压。基于对现有文献的回顾和分析，本文提供了成人患者超说明书使用曲前列汀的全面更新。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

World Journal of Clinical Cases Medicine-General Medicine

自引率

0.00%

发文量

3384

期刊介绍： The World Journal of Clinical Cases (WJCC) is a high-quality, peer reviewed, open-access journal. The primary task of WJCC is to rapidly publish high-quality original articles, reviews, editorials, and case reports in the field of clinical cases. In order to promote productive academic communication, the peer review process for the WJCC is transparent; to this end, all published manuscripts are accompanied by the anonymized reviewers’ comments as well as the authors’ responses. The primary aims of the WJCC are to improve diagnostic, therapeutic and preventive modalities and the skills of clinicians and to guide clinical practice in clinical cases.